Citius Pharmaceuticals, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Citius Pharmaceuticals, Inc. (CTXR) reported Business Acquisition, Pro Forma Net Income (Loss) of -$11.55 million for the 12-month period ending 2016-09-30, per its 10-K filed 2018-12-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2018-12-11
- Citius Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2016-09-30 was -$2.59M.
- Citius Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2016-06-30 was -$3.62M.
- Citius Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2016-03-31 was -$3.70M.
- Citius Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2015-12-31 was -$1.64M.
- Citius Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for fiscal 2016 was -$11.55M.
- Citius Pharmaceuticals, Inc. business acquisition, pro forma net income (loss) for fiscal 2015 was -$6.64M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2016-09-30 | -$2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-11 | -$6.21M derived: sum of 2 quarters · filed 2018-12-11 | -$9.91M derived: sum of 3 quarters · filed 2018-12-11 | -$11.55M 10-K · filed 2018-12-11 |
| 2016-06-30 | -$3.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-14 | -$7.32M derived: sum of 2 quarters · filed 2017-08-14 | -$8.96M 10-Q · filed 2017-08-14 | -$10.94M derived: sum of 4 quarters · filed 2017-12-13 |
| 2016-03-31 | -$3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-15 | -$5.34M 10-Q · filed 2017-05-15 | -$7.32M derived: sum of 3 quarters · filed 2017-12-13 | |
| 2015-12-31 | -$1.64M 10-Q · filed 2017-02-14 | -$3.62M derived: sum of 2 quarters · filed 2017-12-13 | ||
| 2015-09-30 | -$1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-13 | -$6.64M 10-K · filed 2017-12-13 | ||
| 2015-06-30 | -$4.66M 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |